Most Recent
Small business owners who turned to the Bank of Queensland for financial assistance were subject to unfair contract terms that created a "significant imbalance" in the rights of the bank and its customers, a court has held.
The applicant in a class action on behalf of hundreds of thousands of Colonial First State Investments customers has raised concerns about whether he can recover compensation from a CBA life insurance unit that was recently sold to a competitor.
Multinational health technology company Philips may be hit with a class action after its sleep therapy machines were subject to an urgent safety recall over concerns customers could inhale degrading foam.
A former tenured professor is seeking $2 million from the University of New South Wales, alleging she was terminated after making complaints about discrimination, bullying and misuse of her intellectual property.
The Full Federal Court took a "radical" and unorthodox approach with far-reaching consequences by keeping Apple's competition dispute with Fortnite game maker Epic Games in Australia, the Silicon Valley giant has told the High Court.
A high roller with a severe gambling addiction has taken Crown Melbourne to court, alleging the casino’s “predatory” practices caused him to lose more than $4.5 million over three and a half years.
The Australian Competition and Consumer Commission has brought legal action against three major Australian internet providers for allegedly misleading hundreds of thousands of NBN customers.
Sydney's ongoing COVID-19 lockdown has created "logistical" difficulties delaying the release of a long awaited judgment in the ACCC's consumer law case against collapsed private college Phoenix Institute, which was accused of misleading students through the marketing of its courses.
Pharmaceutical giant Bristol-Myers Squibb will fight a case brought by Merck Sharp & Dohme alleging misuse of market power over stage IV melanoma treatments, telling the Federal Court on Friday it denied its rival's claims.
The Australian Securities and Investments Commission has filed court action against a multi-million dollar Western Australian biotech company, alleging it made several misleading representations to the market during the height of the COVID-19 pandemic.